US 12,441,806 B2
Anti-TLR9 agents and compositions and methods for making and using the same
Nicole Vivienne Acuff, San Diego, CA (US); Anagha Ashok Divekar, San Diego, CA (US); and Takatoku Oida, Osaka (JP)
Assigned to BioLegend, Inc., San Diego, CA (US)
Filed by BIOLEGEND, INC., San Diego, CA (US)
Filed on Mar. 22, 2021, as Appl. No. 17/209,093.
Application 17/209,093 is a continuation of application No. PCT/US2019/051976, filed on Sep. 19, 2019.
Claims priority of provisional application 62/736,208, filed on Sep. 25, 2018.
Prior Publication US 2021/0206873 A1, Jul. 8, 2021
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/2896 (2013.01) [G01N 33/6872 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); G01N 2333/70596 (2013.01)] 5 Claims
 
1. An anti-TLR9 agent that binds Toll-like Receptor 9 (TLR9) under laboratory or physiological conditions, wherein the agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, wherein:
each immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2 and CDRH3 amino acid sequences and each immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2 and CDRL3 amino acid sequences selected from sets 1-16:
 
 
 CDRH1
 
 
 
 
 
 
 (SEQ
 
 
 
 CDRL2
 
 
 ID CDRH2 (SEQ ID CDRH3 (SEQ CDRL1 (SEQ (SEQ ID CDRL3 (SEQ
set NO:) NO:) ID NO :) ID NO:) NO:) ID NO:)
 
 
1 NYGMN SISSSSSYIYYADTVKG YTLGIT-IDY LASEDIYNNLA YASTLQD LQDSEYPFT
 
 (1) (3) (9) (22) (24) (31)
 
2 NFGMN SISSTSSYIYYADTVKG ADITIAAPHY LASEDIYNNLA YASSLQD LQDSEFPYT
 
 (2) (4) (10) (22) (25) (32)
 
3 NFGMN SISSTSSYIYYADTVKG ADITIAAPHY LASEDIYNNLA YASSLQD LQDSEFPYT
 
 (2) (4) (10) (22) (25) (32)
 
4 NFGMH SISSTSSYISYADTVKG QDITTP-FDY LASEDIYNNLA YASTLQY LQDSEFPNT
 
 (2) (5) (11) (22) (26) (33)
 
5 NFGMN SISSTSSYIYYADTVKG ADITIAAPHY LASEDIYNNLA YASSLQD LQDSEFPYT
 
 (2) (4) (10) (22) (25) (32)
 
6 NYGMN SISSTSSYIYYADTVKG FTLGIT-LDY LASEDIYNNLA YASSLQD LQDSEYPWT
 
 (1) (4) (12) (22) (25) (34)
 
7 NYGMN SISSSSSYIYYADTVKG SPMGITGFEY LASEDIYNNLA YASSLQD LQDSEYPYT
 
 (1) (3) (13) (22) (25) (35)
 
8 NYGMN SISSSSSYIYYADTVKG HWVGGY-FDY RASEDIYNGLA NANSLHT QQYYDYLPT
 
 (1) (3) (14) (23) (27) (36)
 
9 NFGMN SISSTSSYIYYADTVKG HTIGIT-FDY LASEDIYNNLA YASSLQD LQDSEYPWT
 
 (2) (4) (15) (22) (25) (34)
 
10 NYGMN SISSSSSYIYYADTVKG YTLGIT-LDY LASEDIYNNLA YASSLQD LQESEYPWT
 
 (1) (3) (16) (22) (25) (37)
 
11 NYEMN SISSTSSYIYYADTVKG RGLAVGPFDY LASEDIYNNLA YASSLQD LQDSEYPLT
 
 (1) (4) (17) (22) (25) (38)
 
12 NYGMT SISSTSSYIYYVDTVKG QSITVP-FDY LASEDIYNNLA YTSNLQD LQDSEYPFT
 
 (1) (6) (18) (22) (28) (31)
 
13 NYGMN SISSTSSYIYYADSVKG QSTYGD-FDY RASEDIYNGLA NANTLHI QQYSDYPWT
 
 (1) (7) (19) (23) (29) (39)
 
14 NYEMN SISSTSSYIYYADTVKG RGLAVGPFDY LASEDIYNNLA YASSLQD LQDSEYPLT
 
 (1) (4) (17) (22) (25) (38)
 
15 NYGMN SISSTRSYIYYAETVKG HTVDTP-FAH LASEDIYNNLA HASRLQD LQDSEYPWT
 
 (1) (8) (20) (22) (30) (34)
 
16 NYGMN SISSTSSYIYYADTVKG xTIGIT-FDY LASEDIYNNLA YASSLQD LQDSEYPWT
 
 (1) (4) (21) (22) (25) (34)
 
and wherein all CDR sequences are from the same set.